Risks for familial and contralateral breast cancer interact multiplicatively and cause a high risk

Cancer Research

Volumn 67, Issue 3, 2007, Pages 868-870

  Hemminki, Kari ^a,b   Ji, Anguang ^b   Försti, Asta ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DATA BASE; FAMILIAL CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SWEDEN;

BREAST NEOPLASMS; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS, SECOND PRIMARY; RISK FACTORS; SWEDEN;

EID: 33847054432     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3854     Document Type: Article

References (20)

1. Bermejo JL, Hemminki K. Familial risk of cancer shortly after diagnosis of the first familial tumor. J Natl Cancer Inst 2005;97:1575-9.
2. Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev 1999;8:855-61.
3. Vaittinen P, Hemminki K. Risk factors and age-incidence relationships for contralateral breast cancer. Int J Cancer 2000;88:998-1002.
4. Hemminki K, Granstrom C. Risk for familial breast cancer increases with age. Nat Genet 2002;32:233.
5. Peto J, Mack TM. High constant incidence in twins and other relatives of women with breast cancer. Nat Genet 2000;26:411-4.
6. Hartman M, Czene K, Reilly M, et al. Genetic implications of bilateral breast cancer: a population based cohort study. Lancet Oncol 2005;6:377-82.
7. Johnson N, Fletcher O, Naceur-Lombardelli C, dos Santos Silva I, Ashworth A, Peto J. Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Lancet 2005;366:1554-7.
8. Hemminki K, Li X, Plna K, Granstrom C, Vaittinen P. The nation-wide Swedish family-cancer database-updated structure and familial rates. Acta Oncol 2001;40:772-7.
9. Zelterman D. Advanced log-linear models using SAS. Cary (NC): SAS Institute; 2002.
10. Breslow NE, Day NE. Statistical methods in cancer research. Volume II. The design and analysis of cohort studies. Lyon: IARC Sci Publ; 1987.
11. Greenland S. Interval estimation by simulation as an alternative to and extension of confidence intervals. Int J Epidemiol 2004;33:1389-97.
12. Frodin JE, Ericsson J, Barlow L. Multiple primary malignant tumors in a national cancer registry - reliability of reporting. Acta Oncol 1997;36:465-9.
13. Stenmark-Askmalm M, Gentile M, Wingren S, Stahl O; South-East Sweden Breast Cancer Group. Protein accumulation and gene mutation of p53 in bilateral breast cancer. Acta Oncol 2001;40:56-62.
14. IARC. Some pharmaceutical drugs. In IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon: IARC; 1996.
15. Li CI, Malone KE, Weiss NS, Daling JR. Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst 2001;93:1008-13.
16. Hemminki K, Mutanen P. Genetic epidemiology of multistage carcinogenesis. Mutat Res 2001;473:11-21.
17. Pharoah PD, Antoniou A, Bobrow M, Zimmern HL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002;31:33-6.
18. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006;7:21-33.
19. Rodenhiser D, Mann M. Epigenetics and human disease: translating basic biology into clinical applications. CMAJ 2006;174:341-8.
20. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A 2005;102:10604-9.